Drugs & Therapy Perspectives

, Volume 29, Issue 5, pp 130–134

Rotavirus vaccine RIX4414 (Rotarix®): a guide to its use in preventing rotavirus gastroenteritis in the EU

  • Tracy Swainston Harrison
  • Katherine Lyseng-Williamson
  • Greg L. Plosker
Adis Drug Clinical Q&A

DOI: 10.1007/s40267-013-0034-z

Cite this article as:
Harrison, T.S., Lyseng-Williamson, K. & Plosker, G.L. Drugs Ther Perspect (2013) 29: 130. doi:10.1007/s40267-013-0034-z

Abstract

The human monovalent rotavirus vaccine RIX4414 (Rotarix®) is indicated for the prevention of rotavirus gastroenteritis (RVGE) in infants aged 6 to 24 weeks in the EU. It offers broad sustained protective efficacy against RVGE including severe cases, and reduces the incidence of associated hospitalizations. It does not interfere with the immunogenicity of other paediatric vaccinations, and is considered safe.

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  • Tracy Swainston Harrison
    • 1
  • Katherine Lyseng-Williamson
    • 1
  • Greg L. Plosker
    • 1
  1. 1.AdisAucklandNew Zealand

Personalised recommendations